158 related articles for article (PubMed ID: 38502709)
1. Regulatory Considerations in the Approval of Rezafungin (REZZAYO) for the Treatment of Candidemia and Invasive Candidiasis in Adults.
Smith HL; Bensman TJ; Mishra S; Li X; Dixon CA; Sheikh J; McMaster OG; Joshi A; Rubin DB; Goodwin A; Miller TJ; Danielsen ZY; Syed I; Shukla SJ; Iarikov D; Kim PW; Farley JJ
J Infect Dis; 2024 Mar; ():. PubMed ID: 38502709
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR; Soriano A; Honore PM; Bassetti M; Cornely OA; Kollef M; Kullberg BJ; Pullman J; Hites M; Fortún J; Horcajada JP; Kotanidou A; Das AF; Sandison T; Aram JA; Vazquez JA; Pappas PG
Lancet Infect Dis; 2024 Mar; 24(3):319-328. PubMed ID: 38008099
[TBL] [Abstract][Full Text] [Related]
3. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR; Soriano A; Cornely OA; Kullberg BJ; Kollef M; Vazquez J; Honore PM; Bassetti M; Pullman J; Chayakulkeeree M; Poromanski I; Dignani C; Das AF; Sandison T; Pappas PG;
Lancet; 2023 Jan; 401(10370):49-59. PubMed ID: 36442484
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis.
Sharma D; Vazquez JA
Expert Opin Pharmacother; 2024 Mar; 25(4):339-347. PubMed ID: 38497379
[TBL] [Abstract][Full Text] [Related]
5. Rezafungin: a novel antifungal for the treatment of invasive candidiasis.
Ham YY; Lewis JS; Thompson GR
Future Microbiol; 2021 Jan; 16(1):27-36. PubMed ID: 33438477
[TBL] [Abstract][Full Text] [Related]
6. Rezafungin: First Approval.
Syed YY
Drugs; 2023 Jun; 83(9):833-840. PubMed ID: 37212966
[TBL] [Abstract][Full Text] [Related]
7. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Thompson GR; Soriano A; Skoutelis A; Vazquez JA; Honore PM; Horcajada JP; Spapen H; Bassetti M; Ostrosky-Zeichner L; Das AF; Viani RM; Sandison T; Pappas PG
Clin Infect Dis; 2021 Dec; 73(11):e3647-e3655. PubMed ID: 32955088
[TBL] [Abstract][Full Text] [Related]
8. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix.
August BA; Kale-Pradhan PB
Pharmacotherapy; 2024 May; ():. PubMed ID: 38721866
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
Roepcke S; Passarell J; Walker H; Flanagan S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0091623. PubMed ID: 38014945
[TBL] [Abstract][Full Text] [Related]
10. Invasive
Oliva A; De Rosa FG; Mikulska M; Pea F; Sanguinetti M; Tascini C; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(9):957-975. PubMed ID: 37494128
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
12. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy.
Sofjan AK; Mitchell A; Shah DN; Nguyen T; Sim M; Trojcak A; Beyda ND; Garey KW
J Glob Antimicrob Resist; 2018 Sep; 14():58-64. PubMed ID: 29486356
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and
Miesel L; Cushion MT; Ashbaugh A; Lopez SR; Ong V
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318018
[TBL] [Abstract][Full Text] [Related]
14. Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects.
Flanagan S; Goodman DB; Jandourek A; O'Reilly T; Sandison T
Clin Pharmacol Drug Dev; 2020 May; 9(4):456-465. PubMed ID: 31793231
[TBL] [Abstract][Full Text] [Related]
15. Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
Flanagan S; Walker H; Ong V; Sandison T
Microbiol Spectr; 2023 Jun; 11(3):e0133923. PubMed ID: 37154682
[TBL] [Abstract][Full Text] [Related]
16. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.
Miesel L; Lin KY; Ong V
Pharmacol Res Perspect; 2019 Dec; 7(6):e00546. PubMed ID: 31763045
[TBL] [Abstract][Full Text] [Related]
17. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
18. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.
Arendrup MC; Meletiadis J; Zaragoza O; Jørgensen KM; Marcos-Zambrano LJ; Kanioura L; Cuenca-Estrella M; Mouton JW; Guinea J
Clin Microbiol Infect; 2018 Nov; 24(11):1200-1204. PubMed ID: 29505881
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Rubino CM; Flanagan S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084221. PubMed ID: 34398673
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.
Lakota EA; Ong V; Flanagan S; Rubino CM
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
